ASCO GU 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma - Episode 4
Martin H. Voss, MD, gives an overview of the CLEAR study evaluating lenvatinib plus pembrolizumab in frontline advanced RCC and discusses recent subgroup analyses.
Related Content: